Acasti Pharma Announces TRILOGY 1 Trial Has Achieved 100% Patient Randomization in Patients with Severe Hypertriglyceridemia Apr 15, 2019
Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal Apr 1, 2019
Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd Mar 26, 2019
Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th Mar 13, 2019
Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office Jan 9, 2019
Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan Dec 31, 2018
Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Dec 20, 2018
